SEC Company Response from Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Mar 27, 2018
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: March 27, 2018 · CIK: 0001512762 · Accession: 0001193125-18-097250
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222698
Letter
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
March 27,
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-4628
Attn: Chris Edwards
Re:
Coherus BioSciences, Inc.
Registration Statement on Form S-3 (Registration No. 333-222698)
Ladies and Gentlemen:
On March 22, 2018, Coherus BioSciences, Inc. (the “Company”) submitted a letter requesting that the above-referenced Registration Statement be declared effective on March 27, 2018, at 4:00 p.m., Washington, D.C. time. By this letter the Company hereby withdraws the acceleration request dated March 22, 2018.
Please direct any questions or comments regarding this correspondence to our counsel, Benjamin A. Potter of Latham & Watkins LLP, at (650) 470-4809.
Thank you for your assistance in this matter.
Very truly yours,
Coherus BioSciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 March 27, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-4628 Attn: Chris Edwards Re: Coherus BioSciences, Inc. Registration Statement on Form S-3 (Registration No. 333-222698) Ladies and Gentlemen: On March 22, 2018, Coherus BioSciences, Inc. (the “Company”) submitted a letter requesting that the above-referenced Registration Statement be declared effective on March 27, 2018, at 4:00 p.m., Washington, D.C. time. By this letter the Company hereby withdraws the acceleration request dated March 22, 2018. Please direct any questions or comments regarding this correspondence to our counsel, Benjamin A. Potter of Latham & Watkins LLP, at (650) 470-4809. Thank you for your assistance in this matter. Very truly yours, Coherus BioSciences, Inc. By: /s/ Jean-Frédéric Viret Jean-Frédéric Viret Chief Financial Officer cc: Benjamin A. Potter, Latham & Watkins LLP